Nevirapine: Difference between revisions
From IDWiki
(Created page with " == Pediatric Dosing == === Neonatal HIV prophylaxis === * Dosed by body surface area * ≥34 weeks gestation at birth: 150 mg/m<sup>2</sup> PO once daily for 2 weeks, then q1...")  |
(→â€: added three-dose regimen)  |
||
| Line 6: | Line 6: | ||
* <34 weeks: 10 mg/m<sup>2</sup> PO once daily for 2 weeks, then q12h for 2 weeks |
* <34 weeks: 10 mg/m<sup>2</sup> PO once daily for 2 weeks, then q12h for 2 weeks |
||
* Need to monitor serum trough levels at 7 and 14 days |
* Need to monitor serum trough levels at 7 and 14 days |
||
| + | * For alternative three-dose regimen: |
||
| + | ** 8 mg/dose (1.5-2 kg) or 12 mg (>2 kg) within 48 hours of birth, repeated 48 hours after first dose and 96 hours after second dose |
||
[[Category:HIV]] |
[[Category:HIV]] |
||
Latest revision as of 23:30, 15 November 2019
Pediatric Dosing
Neonatal HIV prophylaxis
- Dosed by body surface area
- ≥34 weeks gestation at birth: 150 mg/m2 PO once daily for 2 weeks, then q12h for 2 weeks
- <34 weeks: 10 mg/m2 PO once daily for 2 weeks, then q12h for 2 weeks
- Need to monitor serum trough levels at 7 and 14 days
- For alternative three-dose regimen:
- 8 mg/dose (1.5-2 kg) or 12 mg (>2 kg) within 48 hours of birth, repeated 48 hours after first dose and 96 hours after second dose
